Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.22

+8.3%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$84.78M
EPS-0.6700
P/E Ratio-3.31
Earnings Date08/05/2026

sera

Interest Expense

Last Annual Value

9.00K

3-Year CAGR

-47%

5-Year CAGR

-65%

10-Year CAGR

-42%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Interest Expense

SERA · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
9.00K
-45.3%-58.7%N/A 
1.09M
N/A-16.3%N/A
5.59M
31.1%254.4%42.8%
0.00
N/AN/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
1.01M
N/A5.9%N/A
0.00
N/AN/AN/A
109.00K
28.0%-12.2%14.6%
0.00
N/AN/AN/A
16.59M
84.9%203.9%N/A
22.00K
-62.5%-49.3%N/A
625.28K
222.2%-0.1%N/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.22, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.22